Unknown PHASE2 INTERVENTIONAL 2-arm NCT04054531

Study of KN046 With Chemotherapy in First Line Advanced NSCLC

An Open-label, Phase II Study of KN046 Evaluating the Efficacy and Safety of KN046 Plus Platinum-based Doublet Chemotherapy as First Line Therapy in Advanced Non-small Cell Lung Cancer Subjects.

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Conditions Non-small Cell Lung Cancer

Interventions Carboplatin KN046 Paclitaxel Pemetrexed

Updated 6 times since 2019 Last updated: Sep 9, 2019 Started: Sep 4, 2019 Primary completion: Mar 1, 2021 Completion: Jun 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-small Cell Lung Cancer, this trial is ongoing. The trial is conducted by Jiangsu Alphamab Biopharmaceuticals Co., Ltd and has accumulated 6 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE2
Oct 2019 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Sep 2019 — Oct 2019 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Data source: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China